World Library  
Flag as Inappropriate
Email this Article

Deflazacort

Article Id: WHEBN0006717614
Reproduction Date:

Title: Deflazacort  
Author: World Heritage Encyclopedia
Language: English
Subject: Prednylidene, Fluprednidene acetate, Fluprednisolone, Fluocortin, Tixocortol pivalate
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Deflazacort

Deflazacort
Systematic (IUPAC) name
(11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione
Clinical data
AHFS/Drugs.com
Routes of
administration
Oral
Pharmacokinetic data
Protein binding 40%
Metabolism By plasma esterases, to active metabolite
Biological half-life 1.1–1.9 hours (metabolite)
Excretion Renal (70%) and fecal (30%)
Identifiers
CAS Registry Number  Y
ATC code H02
PubChem CID:
ChemSpider  N
UNII  Y
KEGG  Y
ChEMBL  N
Chemical data
Formula C25H31NO6
Molecular mass 441.517 g/mol
 N   

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.

Deflazacort is an inactive prodrug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.[1] Its potency is around 70–90% that of prednisone.[2]

It is sold in Bangladesh as Xalcort, marketed by Beacon Pharmaceuticals Limited, in the United Kingdom by Shire under the trade name Calcort;[2] in Brazil as Cortax, Decortil, and Deflanil; in India as MOAID, Defolet(Roussette), DFZ, Decotaz, and DefZot; in Panama as Zamen, Spain as Zamene and in Honduras as Flezacor.[3] It is not available in the United States. In January 2015, the FDA granted fast track status to Marathon Pharmaceuticals to pursue approval of deflazacort as a potential treatment for Duchenne muscular dystrophy. The company expects to make deflazacort available in the United States in 2016. [4]

References

  1. ^ Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical research 12 (7): 1096–100.  
  2. ^ a b "Calcort". electronic Medicines Compendium. June 11, 2008.  Retrieved on October 28, 2008.
  3. ^ "Substâncias: DEFLAZACORT" (in Português). Centralx. 2008.  Retrieved on October 28, 2008.
  4. ^ http://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.